Nirmatrelvir-ritonavir treatment of COVID-19 in a high-risk patient population: A retrospective observational study.
Anna M KaneErica M KeenanKasheng LeeKatherine J HartkopfTrisha A LudwigPhilip J TrapskinJoshua P VanderlooLucas T SchulzPublished in: Journal of the American College of Clinical Pharmacy : JACCP (2022)
A comprehensive program to mitigate drug interactions and prescribe nirmatrelvir-ritonavir ensured timely access to COVID-19 therapy, which may be associated with the prevention of hospitalization and death.